Mr. Gallagher, MBA, CFA, serves as Managing Partner of Laidlaw Venture Partners. He is an Advisor to Athenex (ATNX) and stands on the Board of Directors of Cingulate Therapeutics. Prior to joining Laidlaw, Mr. Gallagher spent the early part of his career at Kidder Peabody (acquired by PaineWebber) and New Vernon Associates. In 2001, Mr. Gallagher Co-Founded BDR Research Group, LLC, an independent sell-side research
firm specializing in healthcare investing, financing and operations, and served as its Chief Executive Officer until November 2010.
In November 2010, he was appointed by the firm Concept Capital, a division of Sanders Morris Harris, as a Managing Director and the Head of Institutional Sales. Mr. Gallagher serves as a strategic consultant for Kinex Pharmaceuticals, a biotechnology firm focused on next-generation therapies in oncology and immunology and was the vice president of business development. In addition, Mr. Gallagher serves on the board of directors of BioSig Technologies, a cardiac focused med-tech company.
Mr. Gallagher is a CFA charter holder, received his MBA from
Pennsylvania State University and holds a B.S. degree in finance from the University of Vermont. He holds the following FINRA licenses: 7, 63, 24, 28, and 65.
Mr. Mr. Gallagher, MBA, CFA, serves as Managing Partner of Laidlaw Venture Partners. He is an Advisor to Athenex (ATNX) and stands on the Board of Directors of Cingulate Therapeutics. Prior to joining Laidlaw, Mr. Gallagher spent the early part of his career at Kidder Peabody (acquired by PaineWebber) and New Vernon Associates. In 2001, Mr. Gallagher Co-Founded BDR Research Group, LLC, an independent sell-side research
firm specializing in healthcare investing, financing and operations, and served as its Chief Executive Officer until November 2010.
In November 2010, he was appointed by the firm Concept Capital, a division of Sanders Morris Harris, as a Managing Director and the Head of Institutional Sales. Mr. Gallagher serves as a strategic consultant for Kinex Pharmaceuticals, a biotechnology firm focused on next-generation therapies in oncology and immunology and was the vice president of business development. In addition, Mr. Gallagher serves on the board of directors of BioSig Technologies, a cardiac focused med-tech company.
Mr. Gallagher is a CFA charter holder, received his MBA from
Pennsylvania State University and holds a B.S. degree in finance from the University of Vermont. He holds the following FINRA licenses: 7, 63, 24, 28, and 65.
Stay In Touch